Genetic Polymorphisms and Ischemic Heart Disease by Fedele, Francesco et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 10
Genetic Polymorphisms and Ischemic Heart Disease
Francesco Fedele, Mariateresa Pucci and
Paolo Severino
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.69621
Abstract
Although the progression in diagnostic tools, prevention strategies, and therapies, isch-
emic heart disease still represents the major cause of mortality and morbidity world-
wide that globally represents an important problem for individuals and healthcare 
resources. By convention, ischemic heart disease is associated with the presence of an 
atherosclerotic plaque that is able to limit the flow in large-medium-sized coronary arter-
ies. Nevertheless, several findings suggest a more complex pathophysiology of ischemic 
heart disease. At this time, there is no well-defined assessment of myocardial ischemia 
pathophysiology. Moreover, several data have identified genetic variations at different 
loci that are linked with ischemic heart disease susceptibility. This chapter aims to exam-
ine this complicated disease and to review the evidence on the genetic heritability acting 
with other factors in determining the presence of ischemic heart disease, due to either an 
obstruction in epicardial vessels or a dysfunction of coronary microcirculation.
Keywords: atherosclerosis, coronary artery disease, coronary microvascular disease, 
endothelial dysfunction, ion channel, ischemic heart disease, myocardial infarction, 
myocardial ischemia, risk factor, single-nucleotide polymorphism
1. Introduction
Nowadays, ischemic heart disease remains a major cause of death and disability worldwide 
for both men and women, although the evolution in prevention and therapy strategies [1]. 
By convention, ischemic heart disease is equated with atherosclerotic plaque due to flow-
limiting obstruction in epicardial coronary arteries. Nevertheless, several findings suggest a 
more complex pathophysiology of this complex disease [2–8]. In fact, it has been showed that 
beyond the presence of epicardial atherosclerotic plaques, coronary microcirculation is cru-
cial in the genesis of ischemic heart disease [9, 10]. In addition, in the last few years, a growing 
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body of data is underlying the importance of heritability acting with other factors in order to 
determine the presence of ischemic heart disease, due to either an obstruction in epicardial 
vessels [11–13] or a dysfunction of coronary microcirculation [14, 15]. In fact, over the past 
decade, genome-wide association studies have identified several loci, explaining a part of the 
ischemic heart disease’s heritability. Existing knowledge of genetic variants affecting risk of 
ischemic heart disease is largely based on genome-wide association studies analysis of com-
mon single-nucleotide polymorphisms.
Therefore, this chapter proposes an overview of the loci that have been identified as connected 
with ischemic heart disease genesis, from epicardial plaque to microvascular dysfunction.
2. Coronary artery disease
Coronary artery disease is defined by the presence of a plaque in the epicardial coronary 
arteries. Usually, the atherosclerotic plaque narrow coronary arteries, decreasing blood 
flow. In subjects with genetic susceptibility factors, coronary artery disease is determined 
by exposure to some risk factors. In the last years, several researches have enhanced our 
understanding of the risk factors as well as the genetic basis of coronary artery disease. 
Some of these factors relate to lifestyles, such as tobacco smoking, lack of physical activity, 
and dietary habits, and are thus modifiable. Other risk factors are also modifiable, such as 
elevated blood pressure, type 2 diabetes, and dyslipidemias, or non-modifiable, such as age, 
male gender, and genetic susceptibility.
To date, more than 50 loci have been identified for susceptibility of coronary artery disease, 
as described by the meta-analysis carried out by the CARDIoGRAMplusC4D Consortium, on 
almost 185,000 cases and controls [11]. Moreover, data from a meta-analysis of genome-wide 
association studies have also been carried out for conventional risk factors and biomarker for 
coronary artery disease, like dyslipidemia and blood pressure, diabetes mellitus, atheroscle-
rosis, inflammation, coagulation, oxidation, and amino acid metabolism, identifying several 
genes for each respective factor [12].
2.1. Genetic polymorphisms and risk factors for coronary artery disease
2.1.1. Dyslipidemia
Lipid metabolism can be altered in different ways, leading to variations in plasma lipoprotein 
function and concentration. Through interaction with other cardiovascular risk factors, dyslip-
idemias may affect the development of coronary artery disease. Dyslipidemias may be related 
to the interaction between genetic predisposition and environmental factors. Up to the present 
time, 12 loci were significantly associated by genome-wide association studies with the concen-
trations of blood lipids and coronary artery disease. Among these, eight loci were associated with 
LDL concentration (ABCG5, ABCG8, ABO, APOB, APOE, LDLR, LPA PCSK9, and SORT1), two 
loci with triglyceride concentration (APOA5 and TRIB1), and one locus with HDL concentration 
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(ANKS1A). At another locus, there was a near-equivalent association for triglyceride and HDL 
(LPL). In severely obese patients, a single-nucleotide polymorphism within the ARPC3 Gene 
Promoter was associated with hypertriglyceridemia [16]. Moreover, among different ethnicities 
Lysosomal Acid Lipase A (LIPA), polymorphisms have been described as associated with sus-
ceptibility to premature coronary artery disease [17]. APOA5 polymorphisms, air pollution, and 
the development of coronary artery disease have been associated, although methylation stud-
ies are needed to examine epigenetic factors associated with those single-nucleotide polymor-
phisms. Another interesting correlation is between TNNT1 variations, HDL levels, and coronary 
artery disease [15]. Finally, it has been suggested that Numb gene haplotypes, the regulating 
factor for intestinal cholesterol absorption and plasma cholesterol level, are related to coronary 
artery disease in Han Chinese [18].
2.1.2. Arterial hypertension
The relationship between blood pressure values and cardiovascular fatal events has been 
determined in several studies [19]. Numerous rare, monogenic forms of hypertension have 
been described, where a single gene mutation explains the pathogenesis of hypertension [20]. 
On the other side, essential hypertension is a heterogeneous disease with a multifactorial 
etiology. Genetic approaches raised the understanding of pathways underlying individual 
variations in blood pressure. Primary analyses evaluated associations between 2.5 million 
genotyped or imputed single-nucleotide polymorphisms (single-nucleotide polymorphisms) 
and SBP and DBP. Several genome-wide association studies and their meta-analyses point to 
a total of 29 single-nucleotide polymorphisms, which are associated with systolic and/or dia-
stolic blood pressure [21]. In particular, latest genome-wide association studies data described 
four coronary artery disease risk loci (CYP17A1- NT5C2, SH2B3, ZC3HC1, GUCY1A3, and 
FES) associated with systolic and diastolic blood pressure [11, 21]. Moreover, endothelial 
nitric oxide synthase (eNOS) single-nucleotide polymorphism G894T significantly increases 
hypertension risk and coronary artery disease [22]. Selective expression of the Rho GTPase-
activating protein ARHGAP42 in vascular smooth muscle cells regulates arterial blood pres-
sure, as it inhibits RhoA-dependent contractility [23]. Furthermore, PDE3A, PRDM6, IGFBP3, 
and KCNK3 genes regulate vascular smooth muscle cells [24]. Particularly, PDE3A is phos-
phodiesterase acting in cyclic GMP metabolism [25], whereas KCNK3 has been related to 
pulmonary hypertension [26]. Other genes related to renal function have been described as 
acting in blood pressure regulation: ARHGAP24 influences podocyte formation [27], OSR1 
influences renal mass and function [28], and SLC22A7 encodes for a renal solute transporter 
[29]; DNA methylation is probably involved in the regulatory pathway linking common 
single-nucleotide polymorphisms with blood pressure, according to data from experimental 
models of hypertension [30].
The single-nucleotide polymorphism Gly460Trp has been associated with hypertension and 
salt sensitivity [31] and an increased risk for coronary heart disease or peripheral vascular 
disease [32] and stroke [33]. An individual with this single-nucleotide polymorphism is a 
responder to diuretics better than wild-type homozygotes [31] in terms mostly of reduction 
of cardiovascular risk [34].
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2.1.3. Diabetes mellitus
Diabetes mellitus has an increasing prevalence worldwide: 360 million people had diabetes in 
2011, of which more than 95% type 2 diabetes. Diabetes mellitus is a complex, chronic disease 
requiring multifactorial risk-reduction strategies beyond glycemic control. Diabetes mellitus 
and cardiovascular disease develop with metabolic abnormalities causing dysfunction in the 
vasculature. Mortality and morbidity in people with diabetes are related to cardiovascular 
disease. Diabetes is a condition defined by an elevated level of blood glucose, and it can be 
classified into general categories: type 1 diabetes (due to b-cell destruction) and type 2 dia-
betes (due to a progressive loss of insulin secretion on the background of insulin resistance).
Usually, type 2 diabetes mellitus is more frequent with obesity, lack of physical activity, in 
women with prior gestational diabetes, in association with hypertension or dyslipidemia, and 
in certain ethnic groups. Insulin resistance plays an important role in the pathophysiology of 
type 2 diabetes mellitus and coronary artery disease: both genetic and environmental factors 
collaborate to its development. In fact, more than 90% of people with type 2 diabetes mellitus 
are obese [35]. Nevertheless, type 2 diabetes mellitus is often associated with a strong genetic 
predisposition, more so than type 1 diabetes. However, the genetics of type 2 diabetes is poorly 
understood. Classically, both the single-nucleotide polymorphism Pro12Ala in the peroxisome 
proliferator-activated receptor gamma (PPARG) gene [36] and the single-nucleotide polymor-
phism Glu23Lys in KCNJ11 gene [37] are common polymorphisms connected with influence 
risk of diabetes mellitus [38]. In particular, single-nucleotide polymorphisms for KCNJ11 have 
been described as involved in the susceptibility of ischemic heart disease, including coronary 
artery disease and CM (see below). Moreover, transcription factor 7-like 2 (TCF7L2) gene is 
involved in diabetes mellitus susceptibility [39]. Some single-nucleotide polymorphisms of the 
gene associated with fat mass and obesity (FTO) [40] have an impact on body mass index 
(BMI). Other single-nucleotide polymorphisms of the gene within or adjacent to hematopoieti-
cally expressed homeobox (HHEX)/insulin degrading enzyme (IDE), CDK5 regulatory subunit 
associated protein 1-like 1 (CDKAL1), insulin-like growth factor 2 mRNA-binding protein 2 
(IGF2BP2), cyclin-dependent kinase inhibitors 2a, b (CDKN2A and CDKN2B), and solute car-
rier family 30, member 8 (SLC30A8) have an effect on insulin secretion [41–43].
Several other loci are implicated in diabetes mellitus as PPARG [44] and KCNJ11 [45] and 
for HNF1B (TCF2) [46] and WFS1 [47]. However, recent data suggest a possible role of other 
genes [48]: Notch homologue 2, Drosophila (NOTCH2) that is known to be involved in pan-
creatic development. Mapping within or adjacent to ADAM metallopeptidase with throm-
bospondin type 1 motif 9 (ADAMTS9), calcium/calmodulin-dependent protein kinase 1D 
(CAMK1D), compared with another zinc finger gene 1 (JAZF1), tetraspanin 8 (TSPAN8)/
leucine-rich repeat containing G-protein coupled (LGR5), and thyroid adenoma associated 
(THADA), the mechanisms involved remain unclear [38].
2.1.4. Atherosclerosis
Cardiovascular disease due to atherosclerosis of the arterial vessel wall and to thrombosis is the 
foremost cause of premature mortality and of disability-adjusted life years (DALYs) in Europe 
and is also increasingly common in developing countries. Atherosclerotic lesions (i.e., atheroma) 
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are asymmetric focal thickenings of the innermost layer of the artery, the intima. The pathophysi-
ology of atherosclerosis suggests an inflammatory disease characterized by arterial plaque rich in 
cholesterol, inflammatory cell infiltrates, and connective tissue [49]. Data from clinical researches, 
studies in animal models, and cell culture experiments found important evidences to the patho-
genesis of atherosclerosis. Several types of research demonstrated an association of IL6R-related 
gene pathways with atherosclerosis and coronary artery disease [50].
In patients with established coronary artery disease, it has been showed that the −174 C 
allele of the IL-6 gene increases the risk for progression of coronary plaques [14]. Moreover, 
patients with the Cox-2 GG single-nucleotide polymorphism have a higher risk of coronary 
artery disease while the Cox-2 (−765G>C) polymorphism is associated with lower interleu-
kin-6 levels [51]. Moreover, multiple single-nucleotide polymorphisms as FGB-FGA-FGG, 
NLRP3, IL1RN, and IRF1-SCL22A5 show a strong association with fibrinogen expression 
and function [52]. Analogously the plaque composition has been associated with specific 
genes: matrix metalloproteinase genes (MMP1, 9, 12, 14) and the co-stimulatory ligands 
CD80 and CD86 [53] are associated with vulnerable plaques. Moreover, indoleamine 2, 
3-dioxygenase 1 (IDO1) and integrin alpha V expression levels seem to be higher in vulner-
able than in stable plaques [53].
In atherosclerotic plaques, there is an overexpression of CB2 gene (CNR2), that is an inflam-
matory marker, compared with normal arteries, whereas stable and vulnerable plaques 
displayed similar CNR2 levels [53]. Lectin-like oxidized low-density lipoprotein receptor 
1 (LOX-1) is the main scavenger receptor for oxidized low-density lipoprotein (ox-LDL) in 
endothelial cells. The single-nucleotide polymorphism c.501G>C determines a single amino 
acid change (K>N at codon 167) reduces ox-LDL binding and uptake. Ox-LDL activated extra-
cellular signal-regulated kinases 1 and 2 (ERK 1/2) is inhibited [54–56].
3. Coronary microvascular disease
The coronary microcirculation is often considered an underwater world beyond the epicar-
dial arteries, often inaccessible for routine investigation, unachievable for targeted treatment. 
However, microcirculation is crucial in the cross talk between perfusion to myocardial demand. 
Pathway for coronary metabolic dilation is determining genetic associations in genes encoding 
for coronary blood flow regulators (i.e., ion channels, nitric oxide synthase, SERCA pump, and 
so on) with the susceptibility for microcirculation dysfunction and ischemic heart disease [57].
Recently, a study comparing the prevalence of single-nucleotide polymorphisms in genes 
encoding coronary ion channels between patients with coronary artery disease or micro-
vascular dysfunction and those with both anatomically and functionally normal coronary 
arteries suggested the possibility of associations between single-nucleotide polymorphisms 
and ischemic heart disease in term of coronary artery disease and microvascular dysfunction 
[57]. In fact, data show that specific single-nucleotide polymorphisms detected in NOS3 gene 
encoding for endothelial nitric oxide synthase (eNOS), as well as in KCNJ8 encoding for the 
inward rectifying subunit of ATP-sensitive potassium channel (Kir6.2) and SCN5A encoding 
for voltage-dependent Na+ channel (Nav1.5) were found to be correlated with ischemic heart 
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disease and microvascular dysfunction [58]. Specifically, the single-nucleotide polymor-
phisms rs5215_GG, rs5218_CT, and rs5219_AA for Kir6.2/KCJ11 could reduce susceptibility 
to ischemic heart disease; the single-nucleotide polymorphism rs5219_AA of Kir6.2/KCNJ11 
may suggest a protecting role against coronary microvascular dysfunction; the rs1805124_GG 
genotype of Nav1.5/SCN5A seems to play a role in coronary artery disease. In the same study, 
also eNOS/NOS3 gene was investigated, demonstrating that rs1799983 polymorphism for this 
gene seems to be an independent risk factor for microvascular dysfunction [57]. The Transient 
Receptor Potential Ankyrin 1 (TRPA1) has been evaluated in vasodilation using KO mice [59]. 
On the other side, smooth muscle Kv7 channels have been associated with the control of vas-
cular reactivity and vasorelaxant responses in coronary circulation [60]. To date, five subtypes 
of Kv7 channels encoded by KCNQ genes have been identified [61]. Kv7.1 and Kv7.4 were 
expressed at higher levels compared to Kv7.2, Kv7.3, and Kv7.5 in coronary arteries [62].
Regarding nitric oxide synthase, the allele “a” of intron 4a/b (eNOS4) has been described 
as a risk factor for patients with microvascular endothelial dysfunction and slow coronary 
flow [63].
Microvascular angina has been also associated with CYP2C19 variants that may affect coro-
nary microvascular dysfunction [64]. Moreover, recent data in the female population showed 
that the specific CYP2C19 poor metabolizer genotype can lead to coronary microvascular 
disorders via inflammation [65].
Nuclear factor (erythroid-derived 2)-like-2 (NRF2) is an antioxidant and cell protective tran-
scription factor that controls antioxidant defenses. NRF2 suppression plays an essential role in 
the development of oxidant stress, endothelial dysfunction, and microvessel rarefaction [66]. 
Moreover, Nox4 has been described as a positive transcriptional regulator of cystathionine- 
γ-lyase (CSE) in endothelial cells. It regulates vascular tone via the modulation of gasotrans-
mitter, hydrogen sulfide (H2S) production [67].
Hypoxia-inducible factor-1 (HIF-1) is a peptide regulator of genes such as heme oxygen-
ase (HO)-1 expressed during hypoxia. HIF-1 activation induces HO-1 expression attenuat-
ing proinflammatory chemokine production by microvascular endothelium in vitro and 
in vivo [68]. The single-nucleotide polymorphism C242T causes p22 (phox) structural 
changes that inhibit endothelial Nox2 activation and oxidative response to tumor necrosis 
factor-α or high-glucose stimulation. The single-nucleotide polymorphism C242T has been 
proposed a protective factor against cardiovascular diseases [69]. Novel regions of genetic 
variations within vascular endothelial growth factor A (VEGFA) and CDKN2B antisense 
RNA1 (CDKN2B-AS1) genes have been associated with coronary microvascular dysfunc-
tion. Furthermore, there were sex-specific differences in single-nucleotide polymorphisms 
which are associated with microvascular dysfunction, in particular, myosin heavy chain 
15 (MYH15), VEGFA, and NT5E. In the male, single-nucleotide polymorphisms for NT5E 
are associated with abnormal coronary flow reserve; however, mutations in NT5E are 
associated with arterial calcification [70]. NT5E gene encodes for CD73 that transforms 
adenosine monophosphate (AMP) to adenosine, supporting a role for this metabolic path-
way in inhibiting vascular calcification [70, 71]. In fact, lack of CD73 leads to a reduction 
in extracellular adenosine levels, causing vascular calcification [72].
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In a meta-analysis of genome-wide association studies, data identified four novel loci on 
chromosomes 19q13, 6q24, 12q24, and 5q14 that were associated with retinal venular cali-
ber. The retinal vasculature is comparable with human microcirculation. Retinal venular cali-
ber has been shown to predict a range of subclinical [73] and clinical cardiovascular disease. 
RASIP1 gene (rs2287921, p = 1.61610225) on chromosome 19q13 is the most significant single-
nucleotide polymorphism associated with retinal venular caliber, and the single-nucleotide 
polymorphisms were located in or adjacent to VTA1 and NMBR genes on chromosome 6q24. 
VTA1 gene encodes for a protein involved in trafficking of the multivesicular body. The sig-
nals for the association on chromosome 12q24 were spread across a large one Mb LD block, 
including genes such as SH2B3, ATXN2, and PTPN11. The most significant single-nucleotide 
polymorphisms at the 5q14 locus were located closest to MEF2C that plays an important role 
in cardiogenesis, epithelial cell survival, and maintenance of blood vessel integrity [74].
Finally, sarcomere gene mutations are associated with adverse remodeling of the microcircu-
lation in hypertrophic cardiomyopathy [75, 76]. In fact, patients with hypertrophic cardiomy-
opathy with sarcomere myofilament mutations are characterized by more severe impairment 
of microvascular function and increased prevalence of myocardial fibrosis, compared with 
genotype-negative individuals [75].
4. Sex differences
Gender difference deserves a separate section. Scientific interest in ischemic heart disease 
in women has grown significantly over the past decades, mostly on clinical aspects. In fact, 
ischemic heart disease differs in term of pathogenesis, symptoms, and prognosis between 
males and females. Several studies show that different single-nucleotide polymorphisms of 
different genes can be involved. Single-nucleotide polymorphisms within genes of MYH15, 
linked to the maintenance of tonic force in vascular smooth muscle cells, VEGFA, involved in 
cell proliferation, migration, and angiogenic potential and NT5E which contributes to overall 
microvessel stiffness were associated with microvascular dysfunction in men [63, 77]. Studies 
on polymorphisms at the cholesteryl ester transfer protein (CETP) locus showed that women 
displayed a higher HDL-C than men and an equally high incidence of coronary heart disease 
in B2 homozygotes as in other genotypes [78]. Thus, in type 2 diabetic patients, the B poly-
morphism seems to exert a modulating role in males only. This may contribute to the loss of 
macrovascular protection in type 2 diabetic females [78].
Moreover, the specific CYP2C19 poor metabolizer has been described as a risk factor for cor-
onary microvascular disorders via inflammation exclusively in the female population [65]. 
Usually, in fertile female exhibits a protection in ischemic injury compared to age-related 
men, a phenomenon designated as sex-specific cardioprotection. PKC-mediated regulation of 
sarcolemmal ATP-dependent K [sarcK(ATP)] channels may account for the gender difference 
in cardioprotection upon both PKC and sarcK(ATP). It involves PKC-dependent sarcolemma 
increase with a major expression of sarcK(ATP) in female [77]. Microcirculation dysfunction 
can also be associated with cardiac hypertrophy, which can be related to the expression of 
Kvβ1.1, particularly in females. In an animal model, Kvβ1 KO female mice have a  growing 
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myosin heavy chain α expression in myocytes. Changes in molecular and cell signaling path-
ways clearly point toward a distinct electrical and structural remodeling consistent with car-
diac hypertrophy in the Kvβ1.1 KO female mice [79].
5. Conclusions
Ischemic heart disease is a common disease that globally represents an important problem 
for individuals and healthcare resources. An enhanced understanding of its  pathophysiology 
is needed. By convention, ischemic heart disease is associated with the presence of an 
 atherosclerotic plaque that is able to limit the flow in large-medium sized coronary arteries. 
Multiple different mechanisms are responsible for symptoms suggesting ischemic heart dis-
ease without apparent flow-limiting obstruction on angiography. In fact, both coronary artery 
disease and coronary microvascular disease can be responsible for an impaired cross talk 
between myocardial demand and oxygen supply. Interestingly, discordance between epi-
cardial coronary function and microvascular function has generated recent interest. Finding 
no obstructive epicardial stenosis, but reduced microvascular function, indicating coronary 
microvascular disease, is associated with a negative prognosis [80].
In contrast, preserved microvascular function in the presence of flow-limiting epicardial ste-
nosis has been associated with a long-term clinical outcome. In fact, several findings suggest 
a complex pathophysiology of ischemic heart disease. Both genetic and lifestyle factors con-
tribute to the individual-level risk of ischemic heart disease, both coronary artery disease and 
coronary microvascular disease. Genetic susceptibility is determined by several single-nucleotide 
polymorphisms of genes encoding for both elements involved in the coronary homeostasis as 
well as for major risk factors for cardiovascular events (i.e., hypertension, diabetes, dyslipid-
emia). Genetic susceptibility is independent of healthy lifestyle behaviors and can be associ-
ated with an increased risk of coronary events, although a healthy lifestyle is associated with 
event risk reductions in rates.
Nowadays, associative hypothesis between single-nucleotide polymorphisms and ischemic 
heart disease has been numerous in literature, and, in some case, researches show speculative 
data with no provided plausible causal mechanism. Large-scale studies in human popula-
tions, genome-wide association studies, and meta-analysis, together with genetic technolo-
gies improvements, are helping the comprehension of genetic susceptibility of ischemic heart 
disease over the last decade. Moreover, a functional understanding of the discovered genetic 
associations with ischemic heart disease could help in the development of novel therapeutic 
strategies. However, we are still distant to the fully knowledge of the pathophysiology of this 
complex disease and the real role of heritability.
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